These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31622082)

  • 1.
    Møllerud S; Hansen RB; Pallesen J; Temperini P; Pasini D; Bornholt J; Nielsen B; Mamedova E; Chalupnik P; Paternain AV; Lerma J; Diaz-delCastillo M; Andreasen JT; Frydenvang K; Kastrup JS; Johansen TN; Pickering DS
    ACS Chem Neurosci; 2019 Nov; 10(11):4685-4695. PubMed ID: 31622082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N1-Substituted Quinoxaline-2,3-diones as Kainate Receptor Antagonists: X-ray Crystallography, Structure-Affinity Relationships, and in Vitro Pharmacology.
    Pallesen J; Møllerud S; Frydenvang K; Pickering DS; Bornholdt J; Nielsen B; Pasini D; Han L; Marconi L; Kastrup JS; Johansen TN
    ACS Chem Neurosci; 2019 Mar; 10(3):1841-1853. PubMed ID: 30620174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Activity Relationship and Solubility Studies of N1-Substituted Quinoxaline-2,3-diones as Kainate Receptor Antagonists.
    Chałupnik P; Vialko A; Pickering DS; Nielsen B; Bay Y; Skov Kristensen A; Hinkkanen M; Szczepańska K; Karcz T; Latacz G; Johansen TN; Szymańska E
    ChemMedChem; 2023 Sep; 18(18):e202300278. PubMed ID: 37387321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding mode of an α-amino acid-linked quinoxaline-2,3-dione analogue at glutamate receptor subtype GluK1.
    Demmer CS; Møller C; Brown PM; Han L; Pickering DS; Nielsen B; Bowie D; Frydenvang K; Kastrup JS; Bunch L
    ACS Chem Neurosci; 2015 Jun; 6(6):845-54. PubMed ID: 25856736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
    Bigge CF; Malone TC; Boxer PA; Nelson CB; Ortwine DF; Schelkun RM; Retz DM; Lescosky LJ; Borosky SA; Vartanian MG
    J Med Chem; 1995 Sep; 38(19):3720-40. PubMed ID: 7562904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors.
    Wilding TJ; Huettner JE
    Mol Pharmacol; 1996 Mar; 49(3):540-6. PubMed ID: 8643094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolylquinoxalinediones carrying a piperazine residue represent highly potent and selective ligands to the homomeric kainate receptor GluR5.
    Lubisch W; Behl B; Henn C; Hofmann HP; Reeb J; Regner F; Vierling M
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2113-6. PubMed ID: 12127516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy.
    Löscher W; Lehmann H; Behl B; Seemann D; Teschendorf HJ; Hofmann HP; Lubisch W; Höger T; Lemaire HG; Gross G
    Eur J Neurosci; 1999 Jan; 11(1):250-62. PubMed ID: 9987029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and structure-activity relationships of novel phenylalanine-based amino acids as kainate receptors ligands.
    Szymańska E; Chałupnik P; Szczepańska K; Cuñado Moral AM; Pickering DS; Nielsen B; Johansen TN; Kieć-Kononowicz K
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5568-5572. PubMed ID: 27765511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.
    Catarzi D; Colotta V; Varano F; Filacchioni G; Galli A; Costagli C; Carlà V
    J Med Chem; 2001 Sep; 44(19):3157-65. PubMed ID: 11543685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist.
    Kohara A; Okada M; Tsutsumi R; Ohno K; Takahashi M; Shimizu-Sasamata M; Shishikura J; Inami H; Sakamoto S; Yamaguchi T
    J Pharm Pharmacol; 1998 Jul; 50(7):795-801. PubMed ID: 9720630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and Affinity of Two Bicyclic Glutamate Analogues at AMPA and Kainate Receptors.
    Møllerud S; Pinto A; Marconi L; Frydenvang K; Thorsen TS; Laulumaa S; Venskutonytė R; Winther S; Moral AMC; Tamborini L; Conti P; Pickering DS; Kastrup JS
    ACS Chem Neurosci; 2017 Sep; 8(9):2056-2064. PubMed ID: 28691798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ( S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation.
    Brogi S; Brindisi M; Butini S; Kshirsagar GU; Maramai S; Chemi G; Gemma S; Campiani G; Novellino E; Fiorenzani P; Pinassi J; Aloisi AM; Gynther M; Venskutonytė R; Han L; Frydenvang K; Kastrup JS; Pickering DS
    J Med Chem; 2018 Mar; 61(5):2124-2130. PubMed ID: 29451794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
    Cai SX; Huang JC; Espitia SA; Tran M; Ilyin VI; Hawkinson JE; Woodward RM; Weber E; Keana JF
    J Med Chem; 1997 Oct; 40(22):3679-86. PubMed ID: 9357535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
    Desos P; Lepagnol JM; Morain P; Lestage P; Cordi AA
    J Med Chem; 1996 Jan; 39(1):197-206. PubMed ID: 8568808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons.
    Bleakman D; Ogden AM; Ornstein PL; Hoo K
    Eur J Pharmacol; 1999 Aug; 378(3):331-7. PubMed ID: 10493110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. It is AMPA receptor, not kainate receptor, that contributes to the NBQX-induced antinociception in the spinal cord of rats.
    Kong LL; Yu LC
    Brain Res; 2006 Jul; 1100(1):73-7. PubMed ID: 16777075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
    Parsons CG; Gruner R; Rozental J
    Neuropharmacology; 1994 May; 33(5):589-604. PubMed ID: 7523977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tritium and deuterium labelling of a kainate receptor antagonist and evaluation as a radioligand.
    Chałupnik P; Marek A; Hovah MEL; Pickering DS; Temperini P; Donbosco S; Szymańska E; Johansen TN
    J Labelled Comp Radiopharm; 2024 Apr; 67(4):120-130. PubMed ID: 38332677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists.
    Mayer ML; Ghosal A; Dolman NP; Jane DE
    J Neurosci; 2006 Mar; 26(11):2852-61. PubMed ID: 16540562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.